BRPI0112928B8 - - Google Patents

Info

Publication number
BRPI0112928B8
BRPI0112928B8 BR0112928A BR0112928A BRPI0112928B8 BR PI0112928 B8 BRPI0112928 B8 BR PI0112928B8 BR 0112928 A BR0112928 A BR 0112928A BR 0112928 A BR0112928 A BR 0112928A BR PI0112928 B8 BRPI0112928 B8 BR PI0112928B8
Authority
BR
Brazil
Application number
BR0112928A
Other languages
Portuguese (pt)
Other versions
BRPI0112928B1 (pt
BR0112928A (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0112928A publication Critical patent/BR0112928A/pt
Publication of BRPI0112928B1 publication Critical patent/BRPI0112928B1/pt
Publication of BRPI0112928B8 publication Critical patent/BRPI0112928B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0112928-7A 2000-07-27 2001-07-27 A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV BRPI0112928B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22149500P 2000-07-27 2000-07-27
US60/221,495 2000-07-27
PCT/US2001/023842 WO2002009643A2 (en) 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Publications (3)

Publication Number Publication Date
BR0112928A BR0112928A (pt) 2003-08-26
BRPI0112928B1 BRPI0112928B1 (pt) 2017-08-29
BRPI0112928B8 true BRPI0112928B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25

Family

ID=22828056

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112928-7A BRPI0112928B1 (pt) 2000-07-27 2001-07-27 A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV

Country Status (12)

Country Link
US (2) US6936261B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1322328B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5511117B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20030024811A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2001280883A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0112928B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2416137C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR6880A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP034447A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2519440T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03000822A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002009643A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1079857B1 (en) 1998-05-29 2006-11-29 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis b/c vaccines
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
ES2539951T3 (es) 1999-10-29 2015-07-07 Novartis Vaccines And Diagnositics S.R.L. Péptidos antigénicos de Neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE378348T1 (de) 2000-01-14 2007-11-15 Us Health Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
NO20002828D0 (no) * 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
BRPI0112928B1 (pt) * 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003095491A2 (en) * 2002-05-14 2003-11-20 Affitech As Antibody screening libraries
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP2258386A3 (en) * 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Neisseria Vaccine composition
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) * 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725256A4 (en) * 2004-02-18 2008-12-31 Univ Newcastle Res Ass VACCINE FORMULATION FOR ADMINISTRATION TO THE LUNGSSCHLEIMHAUT
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
WO2007000342A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007014179A2 (en) * 2005-07-25 2007-02-01 University Of Rochester Method for controlling immunodominance
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2007427A4 (en) * 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES WITH MULTIMETER HSP60 PEPTIDE SUPPORTS
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5702600B2 (ja) * 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
US8999954B2 (en) * 2007-07-03 2015-04-07 Childern's Hospital & Research Center at Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
AU2008272785B2 (en) 2007-07-03 2014-06-12 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
AU2009287339B2 (en) * 2008-08-28 2015-11-26 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816284D0 (en) * 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
ES2658863T3 (es) 2009-06-10 2018-03-12 Glaxosmithkline Biologicals Sa Vacunas que contienen benzonaftiridina
BR112012004276A2 (pt) 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
CN104602702B (zh) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 外膜囊泡
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
KR102779223B1 (ko) 2014-02-28 2025-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
JP7369690B2 (ja) * 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202311230D0 (en) 2023-07-21 2023-09-06 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025021712A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
EP1645631B1 (en) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
EP1079857B1 (en) 1998-05-29 2006-11-29 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis b/c vaccines
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
ES2294821T5 (es) 1998-11-03 2014-03-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS con toxicidad reducida a partir de bacterias gram negativas modificadas genéticamente
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
MXPA01011047A (es) 1999-04-30 2003-10-14 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
EP2258386A3 (en) 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Neisseria Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
US20090035328A1 (en) 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS

Also Published As

Publication number Publication date
EP1322328A2 (en) 2003-07-02
AU2001280883A1 (en) 2002-02-13
WO2002009643A3 (en) 2002-05-30
ECSP034447A (es) 2003-04-25
BRPI0112928B1 (pt) 2017-08-29
US20020110569A1 (en) 2002-08-15
EP1322328A4 (en) 2005-07-20
JP2004512269A (ja) 2004-04-22
WO2002009643A2 (en) 2002-02-07
EP1322328B1 (en) 2014-08-20
CA2416137C (en) 2013-01-29
JP5511117B2 (ja) 2014-06-04
US6936261B2 (en) 2005-08-30
US8980285B2 (en) 2015-03-17
BR0112928A (pt) 2003-08-26
CA2416137A1 (en) 2002-02-07
ES2519440T3 (es) 2014-11-07
CR6880A (es) 2006-08-09
MXPA03000822A (es) 2004-11-01
KR20030024811A (ko) 2003-03-26
US20060029621A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
BE2017C009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C018I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2011C032I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2010C009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2010C008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003511749A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2009C057I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003516774A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2000236815A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BRPI0112928B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2001202191A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002149600A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2000236813A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002092225A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002011876A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002168250A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2001190192A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR0112866A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002026900A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN300955183S (zh) 连接件
ECSDI003780S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003506618A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2001209481A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3133951S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3144126S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.